ESMO 2024 | ETER100: benmelstobart and anlotinib in advanced renal cell carcinoma
Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, discusses the interim results from a Phase III ETER100 trial (NCT04523272) of benmelstobart (TQB2450) plus anlotinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The study shows significant improvements in progression-free survival (PFS) and objective response rate (ORR) with benmelstobart plus anlotinib. The combination demonstrated manageable safety, with similar incidence of grade ≥3 adverse events between treatment arms. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
